tramadol retard stada 100 mg comprimidos de liberacion prolongada efg
laboratorio stada s.l. - tramadol hidrocloruro - comprimido de liberaciÓn prolongada - 100 mg - tramadol hidrocloruro 100 mg - tramadol
tramadol retard stada 150 mg comprimidos de liberacion prolongada efg
laboratorio stada s.l. - tramadol hidrocloruro - comprimido de liberaciÓn prolongada - 150 mg - tramadol hidrocloruro 150 mg - tramadol
tramadol retard stada 200 mg comprimidos de liberacion prolongada efg
laboratorio stada s.l. - tramadol hidrocloruro - comprimido de liberaciÓn prolongada - 200 mg - tramadol hidrocloruro 200 mg - tramadol
tramadol retard teva 100 mg comprimidos de liberacion prolongada efg
teva pharma s.l.u. - tramadol hidrocloruro - comprimido de liberaciÓn prolongada - 100 mg - tramadol hidrocloruro 100 mg - tramadol
tramadol retard teva 150 mg comprimidos de liberacion prolongada efg
teva pharma s.l.u. - tramadol hidrocloruro - comprimido de liberaciÓn prolongada - 150 mg - tramadol hidrocloruro 150 mg - tramadol
tramadol retard teva 200 mg comprimidos de liberacion prolongada efg
teva pharma s.l.u. - tramadol hidrocloruro - comprimido de liberaciÓn prolongada - 200 mg - tramadol hidrocloruro 200 mg - tramadol
tagrisso
astrazeneca ab - osimertinib mesilate - carcinoma, pulmón no microcítico - otros agentes antineoplásicos, inhibidores de la proteína quinasa - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
albumina humana 20% solucion para inyeccion
grey inversiones s.a.c. - solucion para inyeccion - por otros100 ml; clorhidrato de ciprofloxacino monohidrato 582.200000 mg; - bencidamina
laxsen forte capsula
novax e.i.r.l. - capsula - por otros100 ml; cassia angustifolia 26.670000 mg; prunus mexicana 71.430000 mg; - bencidamina
carbatrol 400 mg tableta
instituto quimioterapico s.a. - laboratorio - carbamazepina; - tableta - por vial - - carbamazepina